December 16, 2010 -- In a move to increase its China revenues, H. Lundbeck A/S of Denmark will begin co-promoting Lexapro®, its SSRI-class treatment for depression in the PRC. Previously, Xian-Janssen was exclusively in charge of China marketing for the drug, under an agreement signed in 2002. Both companies agreed to increase their investment in marketing to further increase sales. More details....
